Polaryx Therapeutics (NASDAQ:PLYX) Posts Earnings Results, Misses Estimates By $0.02 EPS

Polaryx Therapeutics (NASDAQ:PLYX) announced its quarterly earnings data on Thursday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02), FiscalAI reports.

Polaryx Therapeutics Stock Performance

PLYX traded up $0.02 during trading on Friday, reaching $1.90. 1,569 shares of the company traded hands, compared to its average volume of 655,182. The company has a market cap of $94.67 million and a P/E ratio of -23.69. Polaryx Therapeutics has a 12-month low of $1.69 and a 12-month high of $48.91. The firm has a fifty day simple moving average of $1.97 and a 200 day simple moving average of $3.08.

Analyst Ratings Changes

Several brokerages have weighed in on PLYX. Wall Street Zen raised shares of Polaryx Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Raymond James Financial started coverage on shares of Polaryx Therapeutics in a research note on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 price objective for the company. Finally, Weiss Ratings upgraded shares of Polaryx Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.67.

About Polaryx Therapeutics

Polaryx Therapeutics is a biotechnology company focused on developing treatments for rare genetic diseases. Its research and development activities target conditions with significant unmet medical needs, including disorders that affect the nervous system and metabolism. The company’s work centers on advancing drug candidates for these conditions. Publicly available information about its specific products, commercial operations, geographic reach and leadership is limited.